NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 109)
Posted On: 01/12/2018 9:28:05 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Receives Initial Coverage from Crystal Equity Research
On January 9, 2018, Crystal Equity Research published an initial report on PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (http://nnw.fm/aO8gG), a biomedical company with a focus on preventative health sciences. Among other highlights, the report noted the company’s recapitalization efforts to fund its development program, as well as the strategic mergers and distribution agreements to address additional markets, including the sports medicine market. The company’s initial product, CELLB9, is an innovative therapy based on blue scorpion venom. The sales from CELLB9 represent the company’s current revenue stream, which helps to balance out research and developmental spending.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
On January 9, 2018, Crystal Equity Research published an initial report on PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (http://nnw.fm/aO8gG), a biomedical company with a focus on preventative health sciences. Among other highlights, the report noted the company’s recapitalization efforts to fund its development program, as well as the strategic mergers and distribution agreements to address additional markets, including the sports medicine market. The company’s initial product, CELLB9, is an innovative therapy based on blue scorpion venom. The sales from CELLB9 represent the company’s current revenue stream, which helps to balance out research and developmental spending.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)PreveCeutical Medical Inc. (PRVCF) Stock Research Links
Scroll down for more posts ▼